MPC Therapeutics launches MitoStem™ to boost CAR-T Cell Durability.

The Geneva-based biotech company announces the commercial launch of MitoStem™, a novel T-cell quality enhancer designed to improve the durability and effectiveness of CAR-T therapies through mitochondrial metabolic reprogramming.

MitoStem™ increases the proportion of stem cell memory T cells (Tscm), a key immune cell subtype strongly linked to long-lasting therapeutic responses. By reprogramming cellular metabolism, MitoStem™ biases T-cell fate toward long-lived immune memory without requiring changes to existing manufacturing protocols. It is fully compatible with leading cell culture media and can be easily integrated into current CAR-T production workflows.

Built on years of research at the intersection of immunology and mitochondrial metabolism, MitoStem™ draws from patented technology and peer-reviewed studies demonstrating that modulation of mitochondrial pyruvate transport enhances T-cell stemness and immune memory formation. Preclinical in vivo data have shown improved tumor clearance and long-term protection.

Unlike approaches that demand complex genetic engineering or lengthy process redevelopment, MitoStem™ is protocol-agnostic, washable, traceable, and designed to support both process control and regulatory confidence.

By adopting a direct-to-market strategy, MPC Therapeutics is making MitoStem™ immediately available to the global research and cell therapy development community, accelerating innovation and bringing scientific breakthroughs closer to patient impact.

➡️ Source: Press Release | 📸©MPC Therapeutics. From L to R: Mathias Wenes (CTO), Raphaël Martinou (CEO), Augustin de Bettignies (CBO), Jean-Claude Martinou (CSO).